Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.

Ali Roghanian, Ingrid Teige, Linda Mårtensson, Kerry L Cox, Mathilda Kovacek, Anne Ljungars, Jenny Mattson, Annika Sundberg, Andrew T Vaughan, Vallari Shah, Neil R Smyth, Bhavwanti Sheth, H T Claude Chan, Zhan-Chun Li, Emily L Williams, Giusi Manfredi, Robert J Oldham, C Ian Mockridge, Sonya A James, Lekh N DahalKhiyam Hussain, Björn Nilsson, J Sjef Verbeek, Gunnar Juliusson, Markus Hansson, Mats Jerkeman, Peter W M Johnson, Andrew Davies, Stephen A Beers, Martin J Glennie, Björn Frendéus, Mark S Cragg

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.'. Together they form a unique fingerprint.

Immunology and Microbiology